Physician profile
Scott H Davis
NPI 1932194131
$874.73
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $169 · 2021: $313 · 2022: $176.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $225.64 | 2019-2021 | |
| Abbvie INC. | $213.72 | 2019-2022 | |
| Chiesi USA, INC. | $187.48 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.59 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.71 | 2019 | |
| Shire North American Group INC | $15.78 | 2019 | |
| Allergan, INC. | $12.67 | 2019 | |
| Pfizer INC. | $12.14 | 2022 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.